Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1361-1372
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Table 3 SVR12 in cirrhotic and non-cirrhotic hepatitis C virus genotype 1b-infected patients with and without resistance-associated polymorphisms at baseline (immediate treatment arm) n (%)
| Patients with cirrhosis - immediate treatment arm | ||||||||
| With RAPs at baseline | Without RAPs at baseline | |||||||
| Mainland China | Russia | South Korea | Overall | Mainland China | Russia | South Korea | Overall | |
| Patients with cirrhosis | ||||||||
| NS5A-L31M/V | 0 | 0 | 0 | 0 | 15/16 (93.8) | 0 | 2/3 (66.7) | 17/19 (89.5) |
| Y93H | 0 | 0 | 0 | 0 | 15/16 (93.8) | 0 | 2/3 (66.7) | 17/19 (89.5) |
| L31M/V or Y93H | 0 | 0 | 0 | 0 | 15/16 (93.8) | 0 | 2/3 (66.7) | 17/19 (89.5) |
| NS3-D168E | 0 | 0 | 0 | 0 | 15/16 (93.8) | 0 | 2/3 (66.7) | 17/19 (89.5) |
| Patients without cirrhosis | ||||||||
| NS5A-L31M/V | 1/1 (100) | 1/1 (100) | 0 | 2/2 (100) | 93/101 (92.1) | 21/22 (95.5) | 8/10 (80.0) | 122/133 (91.7) |
| Y93H | 7/13 (53.8) | 0 | 0/2 (0) | 7/15 (46.7) | 87/89 (97.8) | 22/23 (95.7) | 8/8 (100) | 117/120 (97.5) |
| L31M/V or Y93H | 8/14 (57.1) | 1/1 (100) | 0/2 (0) | 9/17 (52.9) | 86/88 (97.7) | 21/22 (95.5) | 8/8 (100) | 115/118 (97.5) |
| NS3-D168E | 0/1 (0) | 0 | 0 | 0/1 (0) | 94/101 (93.1) | 22/23 (95.7) | 8/10 (80.0) | 124/134 (92.5) |
- Citation: Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1361.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1361